ArticleInternational urology and nephrology2026
C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate C-reactive protein (CRP) at pembrolizumab initiation and paired CRP measurements before first-line chemotherapy and at pembrolizumab initiation as prognostic markers of overall survival (OS) in metastatic urothelial carcinoma (mUC).
methodsWe retrospectively analyzed 346 patients treated with pembrolizumab after platinum chemotherapy. Pre-immunotherapy (pre-IO) CRP was categorized as < 5, 5 to < 20, or ≥ 20 mg/L. Among 333 patients with paired measurements, four joint categories were defined at 5 mg/L. OS was evaluated using Kaplan-Meier methods, restricted mean survival time (RMST), and multivariable Cox regression. Up to 58 patients may overlap an earlier network report.
resultsMedian OS was 19.1, 12.2, and 4.9 months across increasing CRP categories (p < 0.0001). At 24 months, unadjusted RMST was 4.9 months longer below versus at or above 10 mg/L (95% confidence interval [CI] 2.9-6.8). In 322 complete cases, the adjusted hazard ratio was 1.98 for high versus low CRP (95% CI 1.40-2.79) and 1.14 per approximate doubling (95% CI 1.07-1.21). The proportional hazards assumption was not met. Albumin adjustment attenuated the high versus low estimate to 1.26 (95% CI 0.79-2.00). Paired categories separated OS descriptively.
conclusionHigher pre-IO CRP was associated with shorter OS after clinical adjustment, but shared prognostic information with albumin. Paired categories were descriptive. Because the cohort partly overlaps previous work, external validation is required.
Indexed as
Identifiers
42566142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.